2.43
+0.105(+4.53%)
Currency In USD
| Previous Close | 2.32 |
| Open | 2.35 |
| Day High | 2.64 |
| Day Low | 2.34 |
| 52-Week High | 5.46 |
| 52-Week Low | 0.99 |
| Volume | 3.62M |
| Average Volume | 1.65M |
| Market Cap | 221.8M |
| PE | -0.89 |
| EPS | -2.71 |
| Moving Average 50 Days | 1.81 |
| Moving Average 200 Days | 1.84 |
| Change | 0.11 |
If you invested $1000 in Cabaletta Bio, Inc. (CABA) since IPO date, it would be worth $254.34 as of October 08, 2025 at a share price of $2.543. Whereas If you bought $1000 worth of Cabaletta Bio, Inc. (CABA) shares 5 years ago, it would be worth $231.22 as of October 08, 2025 at a share price of $2.543.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cabaletta Bio to Participate in Upcoming Investor Conferences in September
GlobeNewswire Inc.
Aug 27, 2025 12:00 PM GMT
PHILADELPHIA, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoim
Cabaletta Bio Announces Pricing of Public Offering of Securities
GlobeNewswire Inc.
Jun 11, 2025 1:54 PM GMT
PHILADELPHIA, June 11, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specif
Cabaletta Bio Announces Proposed Public Offering of Securities
GlobeNewswire Inc.
Jun 11, 2025 10:15 AM GMT
PHILADELPHIA, June 11, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specif